Federal health advisers say patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.
A panel of Food and Drug Administration experts voted 15-1 to maintain the drugs' approval for patients with chronic kidney disease who are not yet sick enough to receive dialysis. The FDA is not required to follow the group's advice, though it often does.
The panel is now scheduled to discuss altering recommended doses of the drugs to increase their safety.
The FDA is reviewing the three blood-boosting medications from Amgen Inc. after a study published last year that showed kidney disease patients taking them were twice as likely to experience stroke compared with those taking a dummy treatment.
Copyright 2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
KKTV firmly believes in freedom of speech for all and we are happy to provide this forum for the community to share opinions and facts. We ask that commenters keep it clean, keep it truthful, stay on topic and be responsible. Comments left here do not necessarily represent the viewpoint of KKTV 11 News.
If you believe that any of the comments on our site are inappropriate or offensive, please tell us by clicking “Report Abuse” and answering the questions that follow. We will review any reported comments promptly.powered by Disqus